Litcius/Paper detail

LB0006 SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (SAPHYR)

Bhaskar Dasgupta, Sebastian Unizony, Kenneth J. Warrington, Jennifer Sloane Lazar, Angeliki Giannelou, Chad Nivens, Bolanle Akinlade, W. Wong, Yong Lin, Frank Buttgereit, Valérie Devauchelle‐Pensec, Andrea Rubbert‐Roth, Robert Spiera

2022Annals of the Rheumatic Diseases13 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineClinical endpointDiscontinuationRegimenPlaceboPolymyalgia rheumaticaDysgeusiaAdverse effectPrednisoneRandomized controlled trialIntention-to-treat analysisGastroenterologySurgeryGiant cell arteritisDiseasePathologyAlternative medicineVasculitisRheumatoid Arthritis Research and TherapiesHeparin-Induced Thrombocytopenia and ThrombosisMyeloproliferative Neoplasms: Diagnosis and Treatment
LB0006 SARILUMAB IN PATIENTS WITH RELAPSING POLYMYALGIA RHEUMATICA: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL (SAPHYR) | Litcius